Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, August 11, 2005 6:12:34 AM
11.8.2005 / 12:35
TheMarker
Lehman Brothers today repeated an Equal Weight rating for Syneron (TASE, Nasdaq:ELOS), after raising its forecasts for the company following its strong second-quarter financial statement.
For the year 2005, analyst Bob Hopkins expects the Israeli medical-laser technology company to report $1.39 earnings per share, up from $1.14 for 2004 and rising to $1.78 in 2006. Compared with his previous estimates, the change upward is about 25%.
His estimates remain below the Wall Street consensus, however.
For the year 2005, Hopkins now estimates Syneron will present $84.3 million in revenue, an increase of $4 million. For the year 2006, he's looking at $110.4 million in recommendation, up $4.7 million from his former projection. Much of the change is due to expected strong sales of the company's cellulite treatment device, Vela, especially from 2006.
Lehman's 12-month price target is $40, based on 23 times estimated 2006 earnings per share of $1.78, Hopkins writes.
Dubi
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM